

PRIOR AUTHORIZATION POLICY

POLICY: Human Immunodeficiency Virus – Rukobia Prior Authorization Policy

- Rukobia™ (fostemsavir extended-release tablets – ViiV)

REVIEW DATE: 07/22/2020

OVERVIEW

Rukobia, a human immunodeficiency virus type-1 (HIV-1) gp120-directed attachment inhibitor, in combination with other antiretroviral(s) [ARVs], is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.¹

Disease Overview

Heavily treatment-experienced adults account for approximately 6% of adults living with HIV who are on ARV treatment.² These patients have few, if any, treatment options left due to resistance, tolerability, and/or safety considerations. Heavily treatment-experienced adults are at greater risk of progression to acquired immunodeficiency syndrome (AIDS) and death than non-heavily treatment-experienced adults.

Clinical Efficacy

The efficacy of Rukobia was established in one ongoing, Phase III, multicenter, 96-week pivotal study in Heavily treatment-experienced adults with HIV-1 infection failing their current ARV regimen (BRIGHT; n = 371).^{3,6} Eligible patients were ≥ 18 years of age and had failure of their current ARV regimen (baseline HIV-1 RNA ≥ 400 copies/mL), with no viable ARV combination therapy available because of exhaustion of a least four of six ARV classes (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors, CCR5 antagonists, and entry inhibitors). Exhaustion was defined as the elimination of all ARVs within a given class as a fully active option to pair with Rukobia because of resistance, previous adverse events (AEs), or unwillingness to use Fuzeon® (enfuvirtide injection). There were 15 patients who received Trogarzo® (ibalizumab-uiyk injection) in combination with Rukobia.

Guidelines

Treatment with Rukobia is not addressed in guidelines. According to the Department of Health and Human Services Guidelines (December 18, 2019) for the use of antiviral agents in adults and adolescents with HIV infection, treatment-experienced patients with ongoing detectable viremia who lack sufficient treatment options to construct a fully suppressive regimen may be candidates for Trogarzo.⁴ Patients who continue to have detectable viremia and who lack sufficient treatment options to construct a fully suppressive regimen may also be candidates for research studies or expanded access programs, or they may qualify for single-patient access to an investigational new drug as specified in FDA regulations. Guidelines note that Rukobia as an agent in late-stage clinical studies. The International Antiviral Society-USA recommendations for the treatment and prevention of HIV in adults (2018) note that Trogarzo may be useful as a fully active agent for patients with multiclass-resistant virus.⁵

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Rukobia. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of patients treated with Rukobia as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Rukobia to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Rukobia is recommended in those who meet the following criteria:

FDA-Approved Indications

- 1. Human Immunodeficiency Virus (HIV) Infection.** Approve for the duration noted if the patient meets ONE of the following (A or B):
 - A) Initial Therapy.** Approve for 6 months if the patient meets ALL of the following conditions (i, ii, iii, iv, v, and vi):
 - i.** The patient is ≥ 18 years of age; AND
 - ii.** The patient has human immunodeficiency virus type-1 (HIV-1) infection; AND
 - iii.** According to the prescriber, the patient is failing a current antiretroviral regimen for human immunodeficiency virus (HIV); AND
 - iv.** According to the prescriber, the patient has exhausted at least FOUR of the following antiretroviral classes, defined as elimination of all antiretrovirals within a given class due to demonstrated or projected resistance to the agent(s) in that class OR due to significant intolerance:
 - a)** Nucleoside reverse transcriptase inhibitor; OR
Note: Examples of nucleoside reverse transcriptase inhibitors include abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, tenofovir alafenamide, zidovudine.
 - b)** Non-nucleoside reverse transcriptase inhibitor; OR
Note: Examples of non-nucleoside reverse transcriptase inhibitor include delaviridine, efavirenz, etravirine, nevirapine, nevirapine XR, rilpivirine.
 - c)** Protease inhibitor; OR
Note: Examples of protease inhibitors include atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, tipranavir.
 - d)** Fusion inhibitor; OR
Note: Examples of fusion inhibitors include Fuzeon (enfuvirtide for injection).
 - e)** Integrase strand transfer inhibitor; OR
Note: Examples of integrase strand transfer inhibitors include raltegravir, dolutegravir, elvitegravir.
 - f)** CCR5-antagonist; AND
Note: Examples of CCR5 antagonists include Selzentry® (maraviroc tablets).
 - v.** The requested agent will be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents; AND
 - vi.** The requested agent is prescribed by or in consultation with a physician who specializes in the treatment of HIV infection.

- B) Patient is Currently Receiving Rukobia.** Approve for 1 year if the patient meets ALL of the following conditions (i, ii, and iii):
- i.** Patient has human immunodeficiency virus type-1 (HIV-1) infection; AND
 - ii.** The requested agent will continue to be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents; AND
 - iii.** The patient has responded to a Rukobia-containing regimen, as determined by the prescriber.
- Note: Examples of a response are HIV RNA < 40 cells/mm³, HIV-1 RNA $\geq 0.5 \log_{10}$ reduction from baseline in viral load.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Rukobia is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Rukobia™ extended-release tablets [prescribing information]. Research Triangle Park, NC: ViiV/GlaxoSmithKline; July 2020.
2. Hsu R, Fusco J, Henegar C, et al. Clinical outcomes of heavily treatment experienced individuals in the OPERA cohort [abstract PEB0234]. Presented at: 23rd International AIDS Conference; Virtual; July 6-10, 2020.
3. Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. *N Engl J Med.* 2020;382(13):1232-1243.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Last Updated: December 18, 2019. Available at <http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf>. Accessed July 6, 2020.
5. Saag MS, Benson CA, Gandhi RT, et al. Antiviral drugs for treatment and prevention of HIV infection in adults. *JAMA.* 2018;320(4):79-396.
6. Lataillade M, Lalezari J, Molina J-M, et al. Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHT study) [abstract MOAB0102]. Presented at: 10th International AIDS Society Conference on HIV Science; Mexico City, Mexico; July 21-24, 2019.

HISTORY

Type of Revision	Summary of Changes	Review Date
New Policy	--	07/22/2020
DEU Revision	Removal of criterion note referencing CD4 T-cell count	08/03/2020